So I proposed this post hoc analysis to look at more of the totality of effects of these two drugs using a six-component composite end point. The six components were all-cause mortality, MI, stroke, coronary revascularization, hospitalization for heart failure and a composite of adverse renal outcomes
The first few months show the fastest loss, followed by a gradual deceleration as you approach a new metabolic equilibrium
Regulatory Context: The compounded GLP-1 telehealth industry has experienced increased FDA scrutiny in recent years, particularly regarding marketing claims that could mislead consumers about the nature of compounded versus FDA-approved medications
References: Broglio, F., Guarracino, F., Benso, A., Gottero, C., Prodam, F., Granata, R., Avogadri, E., Muccioli, G., Deghenghi, R., & Ghigo, E
If you dont have catalase, thats why you get gray hair